It would be interesting to investigate whether loss of Keap1 and overexpression of Nrf2 status in tumor samples are clinically relevant mechanisms of chemotherapeutic resistance in HNSCC and develop alternative therapy to counter Nrf2 activation. This evidence concerns the gene KEAP1 and neoplasm.